File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Atrial fibrillation

TitleAtrial fibrillation
Authors
Issue Date2012
PublisherThe Lancet Publishing Group. The Journal's web site is located at http://www.elsevier.com/locate/lancet
Citation
The Lancet, 2012, v. 379 n. 9816, p. 648-661 How to Cite?
AbstractThe management of atrial fibrillation has evolved greatly in the past few years, and many areas have had substantial advances or developments. Recognition of the limitations of aspirin and the availability of new oral anticoagulant drugs that overcome the inherent drawbacks associated with warfarin will enable widespread application of effective thromboprophylaxis with oral anticoagulants. The emphasis on stroke risk stratification has shifted towards identification of so-called truly low-risk patients with atrial fibrillation who do not need antithrombotic therapy, whereas oral anticoagulation therapy should be considered in patients with one or more risk factors for stroke. New antiarrhythmic drugs, such as dronedarone and vernakalant, have provided some additional opportunities for rhythm control in atrial fibrillation. However, the management of the disorder is increasingly driven by symptoms. The availability of non-pharmacological approaches, such as ablation, has allowed additional options for the management of atrial fibrillation in patients who are unsuitable for or intolerant of drug approaches.
Persistent Identifierhttp://hdl.handle.net/10722/135233
ISSN
2015 Impact Factor: 44.002
2015 SCImago Journal Rankings: 14.638
ISI Accession Number ID
Funding AgencyGrant Number
Boehringer Ingelheim
Bristol-Myers Squibb
Pfizer
Bayer
Funding Information:

GYHL has received funding for research, educational symposia, consultancy, and lecturing from different manufacturers of drugs used for the treatment of atrial fibrillation and thrombosis. He was Clinical Adviser for the UK National Institute for Health and Clinical Excellence (NICE) guidelines on atrial fibrillation management. He was on the writing committee of the 2010 ESC guidelines on atrial fibrillation, and is Deputy Editor (content expert) for the 9th American College Chest Physicians guidelines on antithrombotic therapy for atrial fibrillation. HFT has received funding for research, educational symposia, consultancy, or lecturing from different manufacturers of devices (Cordis Webster, St Jude Medical, and Medtronic) and drugs (Bayers, Boehringer Ingelheim, Sanofi-Aventis, Bristol-Myers Squibb, Pfizer, and Daiichi Sankyo Sankyo) used for the treatment of atrial fibrillation. DAL has received funding for research, educational symposia, consultancy, and lecturing from different manufacturers of drugs used for the treatment of atrial fibrillation and thrombosis (Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, and Bayer), and is a panellist on the American College Chest Physicians guidelines for the antithrombotic management of atrial fibrillation.

References

 

DC FieldValueLanguage
dc.contributor.authorLip, GYHen_US
dc.contributor.authorTse, HFen_US
dc.contributor.authorLane, DAen_US
dc.date.accessioned2011-07-27T01:30:22Z-
dc.date.available2011-07-27T01:30:22Z-
dc.date.issued2012en_US
dc.identifier.citationThe Lancet, 2012, v. 379 n. 9816, p. 648-661en_US
dc.identifier.issn0140-6736-
dc.identifier.urihttp://hdl.handle.net/10722/135233-
dc.description.abstractThe management of atrial fibrillation has evolved greatly in the past few years, and many areas have had substantial advances or developments. Recognition of the limitations of aspirin and the availability of new oral anticoagulant drugs that overcome the inherent drawbacks associated with warfarin will enable widespread application of effective thromboprophylaxis with oral anticoagulants. The emphasis on stroke risk stratification has shifted towards identification of so-called truly low-risk patients with atrial fibrillation who do not need antithrombotic therapy, whereas oral anticoagulation therapy should be considered in patients with one or more risk factors for stroke. New antiarrhythmic drugs, such as dronedarone and vernakalant, have provided some additional opportunities for rhythm control in atrial fibrillation. However, the management of the disorder is increasingly driven by symptoms. The availability of non-pharmacological approaches, such as ablation, has allowed additional options for the management of atrial fibrillation in patients who are unsuitable for or intolerant of drug approaches.-
dc.languageengen_US
dc.publisherThe Lancet Publishing Group. The Journal's web site is located at http://www.elsevier.com/locate/lancet-
dc.relation.ispartofThe Lanceten_US
dc.subject.meshAnti-Arrhythmia Agents - administration and dosage - adverse effects - therapeutic use-
dc.subject.meshAnticoagulants - administration and dosage - adverse effects - therapeutic use-
dc.subject.meshAspirin - therapeutic use-
dc.subject.meshAtrial Fibrillation - complications - diagnosis - drug therapy - therapy-
dc.subject.meshStroke - etiology - prevention and control-
dc.titleAtrial fibrillationen_US
dc.typeArticleen_US
dc.identifier.emailTse, HF: hftse@hkucc.hku.hken_US
dc.identifier.authorityTse, HF=rp00428en_US
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S0140-6736(11)61514-6-
dc.identifier.pmid22166900-
dc.identifier.scopuseid_2-s2.0-84857236286en_HK
dc.identifier.hkuros187311en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84857236286&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume379-
dc.identifier.issue9816-
dc.identifier.spage648-
dc.identifier.epage661-
dc.identifier.isiWOS:000300629000036-
dc.publisher.placeUnited Kingdom-
dc.identifier.scopusauthoridLip, GYH=35351259800en_HK
dc.identifier.scopusauthoridTse, HF=7006070805en_HK
dc.identifier.scopusauthoridLane, DA=7403211608en_HK
dc.identifier.citeulike10130862-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats